Randomised, double-blind, placebo-controlled study of pivagabine in neurasthenia

被引：0
|
作者：
Pizzolato, G
Cagnin, G
Mancia, D
Caffarra, P
Avanzi, S
Copelli, S
Ciappina, C
Lo Presti, F
Spilimbergo, PG
D'Antonio, E
Di Costanzo, E
Matrango, M
Pastres, P
Urbani, PP
Signorino, M
Simoncelli, M
Provinciali, L
Regnicolo, L
Albano, C
Roccatagliata, G
Rubino, V
Cultrera, S
Fracassi, M
机构：
[1] Univ Padua, Clin Neurol 1, I-35100 Padua, Italy
[2] Univ Parma, Ist Neurol, I-43100 Parma, Italy
[3] Osped Reg Margherita, Div Neurol, Messina, Italy
[4] Osped Civile Conegliano, Serv Psichiatr Diagnosti & Cura, Conegliano, TV, Italy
[5] Osped Torrette, Ist Malattie Sistema Nervoso, Ancona, Italy
[6] Univ Genoa, Ist Malattie Nervose & Mentali, Genoa, Italy
来源：
ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH | 1997年 / 47卷 / 11A期
关键词：
CAS; 69542-93-4; corticotropin releasing factor; neurasthenia; pivagabine; improvement of neurasthenia; Tonerg (R);
D O I：
暂无
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
One hundred and eighteen patients with neurasthenia, as defined by ICD 10(International Classification of Diseases), participated in a randomised, double-blind, placebo-controlled trial of pivagabine (4-[(2,2-dimethyl-1-oxopropyl) amino] butanoic acid, CAS 69542-93-4, Tonerg(R)). Pivagabine administered orally for four weeks. At the end of the trial, active medication was significantly superior to placebo on the Clinical Global Impression (CGI) improvement of illness scale. In addition, pivagabine treatment reduced the physical and mental fatigability of patients, and increased their sense of well-bring.
引用
收藏
页码：1329 / 1331
页数：3
相关论文
共 50 条
  • [1] A randomized, double-blind and placebo-controlled study of a Ganoderma lucidum polysaccharide extract in neurasthenia
    Tang, WB
    Gao, YH
    Chen, GL
    Gao, H
    Dai, XH
    Ye, JX
    Chan, E
    Huang, M
    Zhou, SF
    [J]. JOURNAL OF MEDICINAL FOOD, 2005, 8 (01) : 53 - 58
  • [2] LongoVital® and herpes labialis:: a randomised, double-blind, placebo-controlled study
    Pedersen, A
    [J]. ORAL DISEASES, 2001, 7 (04) : 221 - 225
  • [3] Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis
    Yoshikawa, Hiroaki
    Kiuchi, Takahiro
    Saida, Takahiko
    Takamori, Masaharu
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2011, 82 (09): : 970 - 977
  • [4] Double-blind, placebo-controlled study of quetiapine
    Chawla, J. M.
    [J]. BIPOLAR DISORDERS, 2008, 10 : 42 - 42
  • [5] Randomised, Double-blind, Placebo-controlled Study of Iguratimod in the Treatment of Active Spondyloarthritis
    Li, Yan
    Li, Kunpeng
    Zhao, Zheng
    Wang, Yanyan
    Jin, Jingyu
    Zhang, Jianglin
    Zhu, Jian
    Huang, Feng
    [J]. ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3787 - 3788
  • [6] Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome
    Vercoulen, JHMM
    Swanink, CMA
    Zitman, FG
    Vreden, SGS
    Hoofs, MPE
    Fennis, JFM
    Galama, JMD
    vanderMeer, JWM
    Bleijenberg, G
    [J]. LANCET, 1996, 347 (9005): : 858 - 861
  • [7] RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF NALMEFENE IN PATIENTS WITH ALCOHOL DEPENDENCE
    Gual, A.
    He, Y.
    Torup, L.
    van den Brink, W.
    Mann, K.
    [J]. ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2012, 36 : 137A - 137A
  • [8] A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome
    Jankovic, J.
    Jimenez-Shahed, J.
    Brown, L. W.
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2010, 81 (01): : 70 - 73
  • [9] THROMBOPROPHYLAXIS WITH DALTERPARINE FOR TRANSURETHRAL SURGERY, A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED STUDY
    Maurer, P. M.
    Schuerch, L. S.
    Shahin, O. S.
    Gasser, T.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 265 - 265
  • [10] CHRONIC COUGH AND ESOMEPRAZOLE: A DOUBLE-BLIND, RANDOMISED PLACEBO-CONTROLLED PARALLEL STUDY
    Fathi, H.
    Faruqi, S.
    Thompson, R.
    Wright, C.
    Morice, A. H.
    [J]. THORAX, 2008, 63 : A23 - A23
12345